David R. Walt Receives National Medal of Technology and Innovation

QTRX 01.06.2025

Full Press ReleaseSEC FilingsOur QTRX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - Quanterix to Present at 43rd Annual J.P. Morgan Healthcare Conference
  • 01.14.2025 - Quanterix Provides Update on Financial Performance
  • 01.10.2025 - Quanterix Corporation to Acquire Akoya Biosciences

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 425 Prospectuses and communications, business combinations
  • 01.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
PDF Version

Award represents nation’s highest honor for technological achievement

BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 6, 2025--Quanterix Corporation(NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced thatDavid R. Walt, co-inventor of the Company’s Simoa technology has received the National Medal of Technology and Innovation, bestowed by the President ofthe United States.

Since it was first awarded in 1985, the National Medal of Technology and Innovation has recognized American innovators whose vision, intellect, creativity, and determination have strengthened America’s economy and improved our quality of life. The medal was established byCongressin 1980 and is administered by theU.S. Patent and Trademark Office.

The Medal is awarded to individuals, teams, companies or divisions of companies for their outstanding contributions to America’s economic, environmental and social well-being. The purpose of the National Medal of Technology and Innovation is to recognize those who have made lasting contributions to America's competitiveness, standard of living, and quality of life through technological innovation, and to recognize those who have made substantial contributions to strengthening the nation's technological workforce.

“We are thrilled that David has received the prestigious honor of the National Medal of Technology and Innovation,” saidMasoud Toloue, President and CEO ofQuanterix. “This award is not only a testament to David and his lifelong work, but also demonstrates the power of Simoa in detecting disease early, before symptoms appear, using non-invasive methods. Our best-in-class technology has establishedQuanterixas a leader in Neurology and we are rapidly expanding our presence in other markets such as Immunology and Oncology.”

To learn more aboutQuanterix, visitwww.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visitwww.quanterix.com/simoa-technology.

AboutQuanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease.Quanterixhas been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about theBillerica, Massachusetts-based company athttps://www.quanterix.comor follow us onTwitterandLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106086169/en/

Media Contact:Marissa Klaassenmedia@quanterix.comInvestor Relations Contact:Joshua Youngir@quanterix.com

Source:Quanterix Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com